Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH), from the anterior pituitary gland. GHD can occur at any point during an individual's life, but is primarily defined as being of Childhood onset (CO) or Adult onset (AO). The majority of CO is congenital whereas AO forms tend to be acquired or idiopathic.
This report provides the current prevalent population for GHD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, India and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of GHD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
7 Key Co-morbid Conditions/Features Associated with the Disease
8 Methodology for Quantification of Patient Numbers
9 Top-Line Prevalence for Growth Hormone Deficiency - GHD by Onset Type - Aetiology of GHD - Features of Pituitary Adenomas - Co-morbidities of GHD - Concomitant Pituitary Deficiencies of GHD - Bone Status of GHD Patients